What is ARA-290?

ARA-290, also called cibinetide, is modeled from the helix B surface of erythropoietin. It was designed to keep EPO-like tissue-protective signaling while avoiding classical erythropoietic stimulation of red blood cell production.[5][3]

The strongest human signal is in small fiber neuropathy, especially sarcoidosis-associated neuropathic symptoms and corneal nerve fiber measures. These studies are small, but they are more clinically developed than most research-market peptides.[1][2][4]

ARA-290, cibinetide, and helix B surface peptide are closely related naming lanes for the same EPO-derived tissue-protective peptide concept. The naming should not be confused with erythropoietin itself, because ARA-290 was engineered around nonerythropoietic repair signaling rather than red-blood-cell stimulation.[3][5]

What ARA-290 is investigated for

ARA-290 evidence is grouped by practical use case and injectable route context.Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Sarcoidosis-associated small fiber neuropathy

Injectable

55%Emerging

Sarcoidosis-associated small fiber neuropathy is the strongest ARA-290 human signal, but larger confirmatory trials are still needed.[1][2][4]

Human evidence

Small randomized and follow-up studies support symptom and function signals in sarcoidosis-associated small fiber neuropathy.[1][2][4]

Animal / mechanistic evidence

Mechanistic support centers on tissue-protective innate repair signaling rather than erythropoiesis.[1][2][4]

Corneal nerve regeneration

Injectable

52%Emerging

Corneal nerve findings strengthen the neuropathy story, but durable visual or sensory outcome benefit still needs confirmation.[4][5]

Human evidence

A sarcoidosis-associated small fiber neuropathy study reported improved corneal nerve fiber abundance measured by confocal microscopy.[4][10]

Animal / mechanistic evidence

The same innate repair receptor biology supports nerve-fiber protection and regeneration hypotheses.[5][4]

Diabetic neuropathy and metabolic control

Injectable

50%Emerging

Diabetic neuropathy and metabolic-control findings are promising but less established than the sarcoidosis neuropathy signal.[3][5]

Human evidence

A Phase 2 study reported neuropathic-symptom and metabolic-control findings in type 2 diabetes, but replication is needed.[3][5]

Animal / mechanistic evidence

The tissue-protective mechanism is plausible in metabolic and inflammatory injury contexts.[3][5]

Tissue-protective signaling

Injectable

44%Preliminary

The innate-repair mechanism supports research interest across injury models, but broad tissue-repair treatment claims are not established.[5]

Human evidence

Human tissue-repair outcomes outside neuropathy are not established.[5]

Animal / mechanistic evidence

The innate repair receptor model supports anti-inflammatory and cell-survival signaling.[5]

Chronic pain and neuroinflammation

Injectable

38%Preliminary

Chronic-pain positioning should stay tied to neuropathy and neuroinflammation research rather than generalized analgesic claims.[1][5]

Human evidence

Pain-related human findings come from small neuropathy studies, not broad chronic-pain trials.[1][3]

Animal / mechanistic evidence

Review literature places ARA-290 in tissue-protective and anti-inflammatory signaling relevant to neuropathy and neuroinflammation models.[5]

Evidence snapshot

Overall confidence

Emerging

58%

ARA-290 has meaningful early human neuropathy evidence and a coherent tissue-protective rationale. Sample size, endpoint scope, and missing Phase 3 confirmation keep confidence in the emerging range.[1][4]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

55%

Human evidence

Emerging

Small Phase 2 and randomized studies support sarcoidosis-related small-fiber neuropathy and type 2 diabetes neuropathic-symptom signals. The evidence is still narrow.[1][3][4]

48%

Animal / preclinical

Preliminary

Preclinical tissue-protective studies support the innate-repair rationale behind the human neuropathy work. They should not be generalized into broad tissue-repair claims.[5]

65%

Mechanism support

Moderate

The engineered EPO helix B design and innate-repair-receptor concept give ARA-290 a clear mechanism. It is designed to avoid erythropoietic signaling.[5][3]

Forms & administration

ARA-290 administration is mainly an injectable clinical-research context. Neuropathy-oriented protocols commonly use a short daily course.[1][3][4]

Injectable

Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

Typical Range

Common injectable protocols use 2-4 mg per dose.[1][4]

Frequency

Usually taken once daily.[1]

Timing Considerations

Take at a consistent time, usually morning or evening.[1]

Cycle Length

Common cycles run 4-8 weeks.[1][4]

What to expect

Weeks 1-4

Injectable neuropathy-oriented use may first show changes in burning pain, numbness, sleep disruption, or day-to-day function.[1]

Weeks 4-8

Pain, function, and sensory symptoms are easier to compare against baseline over a full daily course; objective nerve-fiber changes require clinical testing.[4]

After stopping

Pain relief, function, and sensory comfort may hold or fade after the daily course ends.[2][4]

Safety profile

Injectable ARA-290 safety centers on local tolerability, repeated-course exposure, pregnancy avoidance, oncology context, and whether its nonerythropoietic design holds across chronic use. Small studies provide human tolerability context, but not a mature long-term safety profile.[1][3][4]

Common side effects

Injection-site pain or swelling[1]

Cautions

EPO-pathway context[3]
Oncology context[5]

What we don't know

Durable safety and response after repeated or chronic courses are not established.[2][4]

Who ARA-290 is not for

Route-specific avoid and medical-review notes:

Pregnancy or breastfeeding
Avoid because reproductive safety has not been established.[6]
Active cancer or proliferative disease
Medical review is warranted because tissue-protective signaling and growth-factor-adjacent contexts need disease-specific judgment.[5]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

EPO or erythropoiesis-stimulating therapies
EPO or erythropoiesis-stimulating therapy overlaps with ARA-290's EPO-derived biology; the interaction concern is theoretical because ARA-290 was designed to avoid red-cell stimulation.[3]

Regulatory status

United States

ARA-290/cibinetide has no FDA-approved injectable human use as of 2026-06-21. Research, orphan-style development history, or compounded availability does not create FDA review of safety, effectiveness, quality, or market authorization.[6][7][9]

Route	FDA drug approval	503A compounding
Injectable	Not Approved As of 2026-06-21, ARA-290/cibinetide was not FDA-approved as an injectable drug. Clinical-trial activity does not create U.S. market authorization.[6][7]	Not Listed As of 2026-06-21, ARA-290/cibinetide was not identified on FDA's reviewed 503A bulk-substance materials for injectable compounding. Compounded preparations are still not FDA-approved drugs.[8][9]

Injectable

FDA drug approval

Not Approved

As of 2026-06-21, ARA-290/cibinetide was not FDA-approved as an injectable drug. Clinical-trial activity does not create U.S. market authorization.[6][7]

503A compounding

Not Listed

As of 2026-06-21, ARA-290/cibinetide was not identified on FDA's reviewed 503A bulk-substance materials for injectable compounding. Compounded preparations are still not FDA-approved drugs.[8][9]

International

EU/Europe, UK, Canada, and Australia should be checked by local product and claim; trial activity and orphan-style development history should not be read as market approval.

Sports & competition

WADA's 2026 Prohibited List does not specifically name ARA-290, but tested athletes should treat systemic use of a non-approved pharmacological substance as an S0 risk unless cleared through anti-doping review.[12]

How it works

ARA-290/cibinetide is engineered from erythropoietin biology but is meant to avoid classical red-blood-cell stimulation. Its proposed target is innate repair receptor signaling, a tissue-protective pathway discussed around cell-protection, nerve injury, inflammation, and metabolic stress.[3][5]

That mechanism fits sarcoidosis-associated small fiber neuropathy and corneal nerve-fiber endpoints better than broad pain or longevity claims. The injectable route gives systemic exposure, so the key question is whether receptor-level repair signaling produces durable symptom and nerve-fiber improvements in larger, longer trials in treated patients.[1][4][5]

Research gaps & open questions

What the current literature has not yet settled about ARA-290:

Larger late-stage trials still need to confirm whether ARA-290 meaningfully improves pain, daily function, and nerve-fiber health in people with neuropathy.[1][4]

Studies have not established how long treatment should continue, whether benefits last after stopping, or how safe repeated courses are.[2]

Results in sarcoidosis and diabetic neuropathy cannot answer whether ARA-290 works for other conditions; each condition needs its own trials.[3]

Common questions

How is ARA-290 different from EPO?

ARA-290 comes from EPO biology but is engineered for tissue-protective signaling without intended red-blood-cell stimulation.[3][5]

What is the best-supported ARA-290 use case?

Sarcoidosis-associated small fiber neuropathy has the most direct human support, including injectable small-study data on symptoms and corneal nerve fibers.[1][4]

Is ARA-290 FDA-approved?

No. ARA-290/cibinetide has no FDA-approved injectable human use as of 2026-06-21; clinical-trial activity does not create market authorization.[6][7][9]

Myths & misconceptions

Myth

ARA-290 raises red blood cells like EPO.

Reality

It was engineered to retain tissue-protective signaling without classical erythropoietic activity.[3]

Myth

Phase 2 neuropathy data means ARA-290 is an approved neuropathy drug.

Reality

Small Phase 2 studies are promising but do not replace Phase 3 confirmation or regulatory approval.[1][6]

History & discovery

ARA-290, later known as cibinetide, grew out of attempts to preserve erythropoietin's tissue-protective signaling while avoiding the red-blood-cell stimulation that makes EPO clinically complicated.[5][1]

A randomized pilot study tested ARA-290 in sarcoidosis-associated small fiber neuropathy, moving the peptide from innate-repair biology into human symptom research.[1]

A type 2 diabetes study extended the tissue-protection idea to metabolic control and neuropathic symptoms, still in a small clinical setting.[3]

Later sarcoidosis work used corneal nerve fiber abundance as an endpoint, creating a measurable but still limited human evidence thread.[4]

Published research12 studies

[1]

Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.

Molecular medicine (Cambridge, Mass.), 2012 Nov 15. human clinical.

[2]

ARA 290 for treatment of small fiber neuropathy in sarcoidosis.

Expert opinion on investigational drugs, 2014 Apr. review.

[3]

ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.

Molecular medicine (Cambridge, Mass.), 2015 Mar 13. human clinical.

[4]

Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.

Investigative ophthalmology & visual science, 2017 May 1. human clinical.

[5]

Targeting the innate repair receptor to treat neuropathy.

Pain reports, 2016 Jul. review.

[6]

Drugs@FDA/openFDA query for ARA-290

U.S. Food and Drug Administration / openFDA. database query.

[7]

Drugs@FDA/openFDA query for Cibinetide

U.S. Food and Drug Administration / openFDA. database query.

[8]

Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act

U.S. Food and Drug Administration, 2026-05-14. regulatory.

[9]

Compounding and the FDA: Questions and Answers

U.S. Food and Drug Administration. official guidance.

[10]

Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis

ClinicalTrials.gov. clinical trial registry.

[11]

ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes)

ClinicalTrials.gov. clinical trial registry.

[12]

The 2026 List of Prohibited Substances and Methods

World Anti-Doping Agency, 2026. regulatory.